Being diagnosed with a rare cancer like GIST can make finding resources more challenging. While this is not an exhaustive list of resources available, these organizations can provide a wealth of information and assistance.
Director of Communications Mary Garland shares these top ten tips for caregivers for this GIST journey.
Five GISTers and four caregivers attend the luncheon at Europa Restaurant and Bakery. Besides a great meal, attendees were able to meet each other and share our journeys through their GIST journeys.
The Life Raft Group announces Steve Pontell, Esq. as the newest addition to our Board of Directors.
Dr. Andrew Blakely, Program Director, Surgical Oncology Research Fellowship, National Cancer Institute, National Institutes of Health, shares how his team works with adult SDH-deficient GIST patients.
Margo Shoup is a doctor on a mission. She moved from the Chicago area to Connecticut almost a year ago and has been the catalyst behind the creation of specialized disease teams targeting cancer care in a health system that covers an extensive area from western Connecticut up into the Hudson Valley of New York State.
Earlier this month, members of the LRG staff were invited to the Rutgers Cancer Institute of New Jersey by sarcoma specialist Dr. Roman Groisberg.
Our Rare Disease Day offering is a whitepaper titled 'Partnership for Survival – Treating the Rarest of the Rare' detailing how a collaboration with the NIH has become a model for other advocacy groups and researchers.
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Richard Schoenbohm shares his story.
Deciphera Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ripretinib for Priority Review. Ripretinib is an investigational broad-spectrum KIT and PDGFRa inhibitor for the treatment of patients with gastrointestinal stromal tumors (GIST).
